Objective
"More than a billion people suffer from anemia. The only drug used to symptomatically increase red blood cell production in anemic patients is recombinant erythropoietin (Epo). While Epo injections effectively promote red blood cell production in patients suffering low endogenous Epo production, aplastic anemia and anemia associated with cancer, inflammation and infection do not respond well to recombinant Epo treatment.
Aim A: Since there is a great need for new drugs that can treat Epo-resistant anemias the first aim of ERYTHROTHERAPY is to identify novel drug target for production of Epo-responsive cells. Using next-generation mRNA sequencing we identified 250 candidate genes that have the potential to be targeted by drugs and are highly expressed in red blood cell progenitor cells. RNA interference based screening strategies will be used to systematically characterize which if these genes can be targeted to promote red blood cell progenitor proliferation. If successful this study will lead to development of a novel class of erythropoiesis stimulating agents able to manage conditions that today lack pharmacological treatment.
Aim B: The second goal of this project is to identify mechanism-based treatment strategies for Diamond-Blackfan anemia (DBA; OMIM #105650). All known DBA disease genes encode for ribosomal protein (RP) genes. Despite the recent advances in DBA genetics the pathophysiology remains elusive, which until now has prevented development of disease-specific therapies.
In order to develop effective and specific DBA drugs the ERYTHROTHRAPY proposal uses an animal model for DBA to identify the molecular mechanisms linking RP-deficiency to anemia and bone marrow failure. Since limitations of previous mouse models for DBA make them unsuitable for this research strategy we generated a novel RP-deficient DBA mouse by taking advantage of Doxycycline-regulatable RNA interference. The drug-inducible strategy allows reversible and dose-dependent downregula"
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine physiology pathophysiology
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences clinical medicine oncology
- medical and health sciences clinical medicine hematology
- natural sciences biological sciences genetics RNA
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2011-CIG
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MC-CIG - Support for training and career development of researcher (CIG)
Coordinator
22100 LUND
Sweden
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.